Skip to main content

Immunicum AB (publ) Announces Outcome of Subscription in Incentive Program LTI 2021/2024

Press Release

29 September 2021

Immunicum AB (publ) Announces Outcome of Subscription in Incentive Program LTI 2021/2024

Immunicum AB (publ) announced today the outcome of the subscription of employee stock options and restricted share units in the incentive program LTI 2021/2024 resolved by the Annual General Meeting on 4 May 2021. In total, 1,286,092 employee stock options and 660,000 restricted share units have been subscribed, representing a dilution of 0.97 percent if all employee stock options and restricted share units are exercised.

The Annual General Meeting on 4 May 2021 resolved to implement a performance-based incentive program (“LTI 2021/2024”). The incentive program includes employee stock options (the “Employee Stock Option Program 2021/2024) and restricted share units (the “Restricted Share Unit Program 2021/2024”).

The Employee Stock Option Program 2021/2024
The Employee Stock Option Program 2021/2024 is directed to senior executives and key employees in the group and comprises of a maximum of 1,678,453 employee stock options. In total, 1,286,092 employee stock options have been subscribed and allocated. Each employee stock option entitles the holder a right to subscribe for one (1) new share in the Company during the exercise period at a subscription price corresponding to SEK 7.35, which corresponds to 140 per cent of the volume-weighted average price paid during the period commencing at 5 May 2021 up until and including 19 May 2021 of the noted paid prices for shares in the Company. The exercise period commences on 1 September 2024 up to and including 31 October 2024.

The Restricted Share Unit Program 2021/2024
The Restricted Share Unit Program 2021/2024 is directed to other employees in the group and comprises a maximum of 834,300 restricted share units. In total, 660,000 restricted share units have been subscribed and allocated. Each restricted share unit entitles the holder a right to subscribe for one (1) new share in the Company during the exercise period at a subscription price corresponding to the quota value of the share. The current quota value is SEK 0.05 per share. The exercise period commences on 1 September 2024 up to and including 31 October 2024.

The information in this press release is information that Immunicum AB (publ) is obliged to disclose pursuant to Nasdaq Stockholm’s Rule Book for Issuers. The information was released for public disclosure through the agency of the contact persons set out below at 8:00 am CEST on 29 September, 2021.

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

Telephone: +31 713 322 627

E-mail: ir@immunicum.com

INVESTOR RELATIONS

Kristina Windrup Olander

Spikinc AB

Telephone: +46 72 545 34 74

E-mail: ir@immunicum.com

MEDIA RELATIONS

Sophia Hergenhan & Jacob Verghese

Trophic Communications

Telephone: +49 89 2388 7731

E-mail: immu@trophic.eu


ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.
www.immunicum.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.